PALATIN COMPLETES ENROLLMENT IN PT-141 TRIALS FOR FEMALE SEXUAL DYSFUNCTION AND MALE ERECTILE DYSFUNCTION

Palatin Technologies has completed enrollment in separate Phase IIa clinical trials evaluating PT-141 in patients experiencing female sexual dysfunction (FSD) and male erectile dysfunction (ED).

The FSD clinical trial was designed to evaluate the safety and efficacy of PT-141 in premenopausal women with a diagnosis of FSD. The ED clinical trial was designed to evaluate the safety and efficacy of PT-141 co-administered with sildenafil (Viagra) in men with a diagnosis of ED.

The company is currently analyzing the data for both in-clinic trials and plans to release the results later this quarter. PT-141 is Palatin's lead drug candidate for the treatment of male and female sexual dysfunction and is being jointly developed in collaboration with King Pharmaceuticals.